Antonio Calles

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer

Antonio Calles, Xiaoyun Liao, Lynette M. Sholl et al. · Journal of Thoracic Oncology · 2015 · 290 citations · Full text

Medicine, Immunology, Oncology +17

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 258 citations

Medicine, Oncology, Pharmacology +17

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

Irene Braña, Antonio Calles, Patricia LoRusso et al. · Targeted Oncology · 2014 · 210 citations

Medicine, Oncology, Pharmacology +15

Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis

Paaladinesh Thavendiranathan, Lili Zhang, Amna Zafar et al. · Journal of the American College of Cardiology · 2021 · 188 citations · Full text

Life Sciences, Cardiology, Immunology +16

A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer

Frederick H. Wilson, Cory M. Johannessen, Federica Piccioni et al. · Cancer Cell · 2015 · 174 citations · Full text

Medicine, Cancer Biology, Oncology +16